Amiodarone: An effective antiarrhythmic drug with unusual side effects

Heart

Volumn 96, Issue 19, 2010, Pages 1593-1600

  Van Erven, Lieselot ^a   Schalij, Martin J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ERYTHROMYCIN; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; QUINIDINE; SOTALOL; STEROID; TACROLIMUS; THIAZIDE DIURETIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CONTINUOUS INFUSION; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIDIDYMITIS; ERECTILE DYSFUNCTION; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART CONDUCTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE ARRHYTHMIA; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOKALEMIA; HYPOTENSION; HYPOTHYROIDISM; INTERSTITIAL PNEUMONIA; LIVER CIRRHOSIS; LIVER FUNCTION; LOADING DRUG DOSE; MALAISE; MEMORY DISORDER; OPTIC NEURITIS; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; QRS COMPLEX; QT INTERVAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINUS ARREST; SKIN DISCOLORATION; SLEEP DISORDER; TORSADE DES POINTES; TREMOR;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; DRUG INTERACTIONS; EYE DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; PNEUMONIA;

EID: 77957306401     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.152652     Document Type: Review

References (34)

1. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circ 1999;100:2025-34.
2. Martino E, Bartalena L, Bogazzi F. The effects of amiodarone on the thyroid. Endocr Rev 2001;22:240-254. This is an excellent and extensive review on the effect of amiodarone on the thyroid.
3. Buchinger W, Lorenz-Wawschinek O, Semlitsch G, et al. Thyrotropin and thyroglobulin as an index of optimal iodine intake: correlation with iodine excretion of 39,913 euthyroid patients. Thyroid 1997;7:593-7. (Pubitemid 27371798)
4. Julian DG, Camm AJ, Frangin MJ, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-74.
5. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349;675-82. The studies in references 4 and 5 were performed to evaluate the effect of amiodarone, given directly after myocardial infarction, with negative results.
6. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Effect of encainide and flecainide on mortality in infarction. N Engl J Med 1989;321:406-12.
7. Yalta K, Turgut O, Yilmaz M, et al. Dronedarone: a promising alternative for the management of atrial fibrillation. Cardiovasc Drugs Ther 2009;23:385-93. Review that nicely summarises studies that have been done on the effect on dronedarone.
8. Ypenburg C, van Erven L, Bleeker GB, et al. Benefit of combined resynchronization and defibrillator therapy in heart failure patients with and without ventricular arrhythmias. J Am Coll Card 2006;48:464-70.
9. Zecchin M, di Lenarda A, Proclemer A, et al. The role of implantable cardioverter defibrillator for primary vs secondary prevention of sudden death in patients with idiopathic dilated cardiomyopathy. Europace 2004;6:200-4. References 8 and 9 are examples of widespread amiodarone use in secondary prevention patients.
10. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000;342:913-18.
11. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-72. References 10 and 11 report large trials showing the superiority of amiodarone in patients with atrial fibrillation to maintain sinus rhythm.
12. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
13. Van Gelder ICD, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40. Reference 12 and 13 are classical studies on rhythm versus rate control in patients with atrial fibrillation. This is a very important issue when deciding whether amiodarone may be discontinued and rate control can be installed.
14. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.
15. Kudenchuk PJ, Cobb LA, Copass MK. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999;341:871-8.
16. Dorian P, Cass D, Cooper R, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 2002;346:884-90. (Pubitemid 34984636)
17. Leeuwenburgh BP, Versteegh MI, Maas JJ, et al. Should amiodarone or lidocaine be given to patients who arrest after cardiac surgery and fail to cardiovert from ventricular fibrillation? Interact Cardiovasc Thorac Surg 2008;7:1148-51. References 15e17 report the superiority of amiodarone over lidocaine in a variety of acute settings.
18. Cascade Investigators. Cardiac arrest in Seattle: conventional versus amiodarone drug evaluation. Am J Cardiol 1991;125:109-20.
19. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC study: a randomized trial. JAMA 2006:295:165-71.
20. Man KC, Williamson BD, Niebauer M, et al. Electrophysiologic effects of sotalol and amiodarone in patients with sustained monomorphic ventricular tachycardia. Am J Cardiol 1994;74:1119-23. References 18e20 are classical drug trials that compared amiodarone to other antiarrhythmic drugs with respect to ventricular arrhythmias.
21. Kamath GS, Mittal S. The role of antiarrhythmic drug therapy for the prevention of sudden cardiac death. Progr Cardiovasc Dis 2008;50:439-48. (Pubitemid 351636106)
22. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-237. This reference refers to the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
23. Kies Ph, Boersma E, Bax JJ, et al. Determinants of recurrent ventricular arrhythmia or death in 300 consecutive patients with ischemic heart disease who experienced aborted sudden death: data from the Leiden out-of-hospital cardiac arrest study. J Cardiovasc Electrophysiol 2005;16:1049-56.
24. Desai AD, Chun S, Sung RJ. The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med 1997;127:294-303. (Pubitemid 27352051)
25. Kowey PR, Marinchak RA, Rials SJ, et al. Intravenous amiodarone. J Am Coll Cardiol 1997;29:1190-8. References 24 and 25 report on the effects of intravenous amiodarone and the differences with oral amiodarone.
26. Brendorp B, Pedersen O, Torp-Pedersen C, et al. A benefit-risk assessment of class III antiarrhythmic agents. Drug Saf 2002;25:847-65.
27. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev 2005;26:704-28. This is an extensive and interesting review on the effect of thyroid hormone on the heart.
28. Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med 2005;118:706-14. Clearly written, very practical review on the interaction between amiodarone and the thyroid.
29. Martino E. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984;101:28. (Pubitemid 14088063)
30. Tanda ML, Bogazzi F, Martino E, et al. Amiodarone-induced thyrotoxicosis: something new to refine the initial diagnosis? Eur J Endocr 2008;159:359-61.
31. Camus PH, Fanton A, Bonniaud PH, et al. Interstitial lung disease induced by drugs and radiation. Respiration 2004;71:301-26.
32. Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol 2001;2:253-62. (Pubitemid 33717959)
33. Mantyjarvi M, Tuppurainen K, Ikaheimo K. Ocular side effects of amiodarone. Surv Ophthalmol 1998;42:360-6.
34. Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000;26:1741-8. References 31e34 describe several non-thyroidal side effects of amiodarone.